Cited 12 times in
Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강창무 | - |
dc.contributor.author | 이우정 | - |
dc.contributor.author | 최성훈 | - |
dc.contributor.author | 황호경 | - |
dc.date.accessioned | 2014-12-18T08:49:18Z | - |
dc.date.available | 2014-12-18T08:49:18Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0960-7404 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/87014 | - |
dc.description.abstract | Pancreatic ductal adenocarcinoma is known as one of the most fatal malignant diseases in gastrointestinal system. Approximately 20% of patients are deemed resectable at the time of diagnosis. Preoperative neoadjuvant therapy to the borderline resectable pancreatic cancer (BRPC) has been challenged to achieve down-staging of cancer, to avoid unnecessary major operation if the pancreatic cancer progresses and distant metastasis develops during preoperative treatment, and to avoid delayed adjuvant treatment after major operation due to postoperative complications and poor general condition after major surgery. However, there are some controversial issues influencing the clinical interpretation of surgical and oncologic outcomes of pancreatectomy following neoadjuvant treatment in managing BRPC. This manuscript reviews the current controversial issues in managing BRPC in order to enhance proper understanding the current status and potential role of neoadjuvant treatment in managing BRPC. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | SURGICAL ONCOLOGY-OXFORD | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Carcinoma, Pancreatic Ductal/surgery | - |
dc.subject.MESH | Carcinoma, Pancreatic Ductal/therapy* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoadjuvant Therapy* | - |
dc.subject.MESH | Pancreatectomy* | - |
dc.subject.MESH | Pancreatic Neoplasms/surgery | - |
dc.subject.MESH | Pancreatic Neoplasms/therapy* | - |
dc.subject.MESH | Prognosis | - |
dc.title | Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Chang Moo Kang | - |
dc.contributor.googleauthor | Ho Kyoung Hwang | - |
dc.contributor.googleauthor | Sung Hoon Choi | - |
dc.contributor.googleauthor | Woo Jung Lee | - |
dc.identifier.doi | 10.1016/j.suronc.2013.02.007 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04085 | - |
dc.contributor.localId | A02993 | - |
dc.contributor.localId | A00088 | - |
dc.contributor.localId | A04497 | - |
dc.relation.journalcode | J02709 | - |
dc.identifier.eissn | 1879-3320 | - |
dc.identifier.pmid | 23518243 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S096074041300025X | - |
dc.subject.keyword | Pancreatic cancer | - |
dc.subject.keyword | Neoadjuvant treatment | - |
dc.subject.keyword | Borderline resectable pancreatic cancer | - |
dc.contributor.alternativeName | Kang, Chang Moo | - |
dc.contributor.alternativeName | Lee, Woo Jung | - |
dc.contributor.alternativeName | Choi, Sung Hoon | - |
dc.contributor.alternativeName | Hwang, Ho Kyoung | - |
dc.contributor.affiliatedAuthor | Choi, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Woo Jung | - |
dc.contributor.affiliatedAuthor | Kang, Chang Moo | - |
dc.contributor.affiliatedAuthor | Hwang, Ho Kyoung | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 22 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 123 | - |
dc.citation.endPage | 131 | - |
dc.identifier.bibliographicCitation | SURGICAL ONCOLOGY-OXFORD, Vol.22(2) : 123-131, 2013 | - |
dc.identifier.rimsid | 32097 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.